Why Is Beta Bionics Stock Up Today?
The FDA cleared Beta Bionics' Mint patch pump for a planned first-quarter 2027 launch. The stock dropped to $14.24 before the open and was up 4.34% on the session at 12:22 ET.
- The FDA cleared Mint, a two-piece patch pump with 3-day wear and no charging; the full U.S. launch is planned for the first quarter of 2027.
- Beta Bionics submitted its 3D Intelligence algorithm to the FDA and plans iLet 3D by the end of 2026.
- The stock fell to $14.24 in premarket trading after the release, then traded at $17.29 by 12:22 ET (measured).
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +session | +1m % | +session % |
|---|---|---|---|---|---|---|
| BBNX | 16.66 | 16.66 | 16.91 | 17.00 | +1.50% | +2.04% |
Beta Bionics stock is up today after the FDA cleared Mint, the company's first patch insulin pump, and Senseonics agreed to connect its year-long glucose sensor to the iLet. The clearance crossed MoveSurge's tape at 07:30:00 ET; the stock was 1.501% higher a minute later, fell to $14.24 before the open, and traded at $17.29 at 12:22 ET, up 4.34% on the session.
What the FDA cleared
Mint is a two-piece patch pump made of a reusable part and a disposable part. Beta Bionics listed these specifications:
| Feature | Mint |
|---|---|
| Wear time | 3 days plus a 12-hour grace period |
| Insulin reservoir | 200 units |
| Charging | None required |
| Water resistance | IPX8, to 5 feet for 60 minutes |
| Control | iOS and Android smartphone app, with over-the-air updates |
| Glucose sensors | Dexcom G7, Dexcom G7 15 Day, Abbott FreeStyle Libre 3 Plus |
The company expects to begin the full U.S. commercial launch in the first quarter of 2027, to sell Mint only through the pharmacy channel, and to have manufacturing capacity for at least 1.5 million disposable Mint units in 2027. It said Mint will modestly dilute its 2027 gross margin and become highly accretive to its long-term gross margin at scale.
3D Intelligence and the Senseonics deal
Beta Bionics also unveiled 3D Intelligence, a new insulin dosing algorithm it has submitted to the FDA through a 510(k) application. It offers three selectable dosing experiences, one of which keeps the algorithm iLet users have today. The company expects to sell it as iLet 3D in the U.S. by the end of 2026 and as Mint 3D when Mint is fully launched, both subject to FDA clearance.
At 07:00:03 ET, half an hour before the clearance, Senseonics announced a partnership to connect its Eversense 365 sensor, which lasts a year, to the iLet Bionic Pancreas. Senseonics expects to finish development in the fourth quarter of 2026 and plans a commercial launch of the combined system in the same quarter.
How the stock traded, measured minute by minute
The first trades after the release were small: the stock printed $16.91 a minute after 07:30 ET and $17.00 ten minutes after, 2.041% above the last print of $16.66, on 501 shares. The heavier trading came after that window closed, when 52,978 shares changed hands and the price fell to $14.24 by 07:42 ET, 14.53% below the pre-release print.
| Minute (ET) | High | Low | Close | Shares |
|---|---|---|---|---|
| 07:30 | $16.91 | $16.91 | $16.91 | 354 |
| 07:32 | $17.00 | $17.00 | $17.00 | 147 |
| 07:40 | $16.71 | $15.00 | $15.00 | 26,339 |
| 07:41 | $15.00 | $14.79 | $14.79 | 25,200 |
| 07:42 | $14.51 | $14.24 | $14.25 | 1,439 |
| 07:43 | $14.25 | $14.25 | $14.25 | 0 |
By 12:22 ET the stock was 21.41% above that premarket low and 3.78% above the last print before the release. Friday's close was $16.57.
The road to Mint
- May 21, 2026 — Beta Bionics said it expected to fully commercialize Mint by the end of the second quarter of 2027, basing the timeline on the FDA's initial responses to its Mint 510(k) application and on progress scaling manufacturing.
- July 29, 2026 — second-quarter results; the company raised its full-year 2026 gross margin guidance to 58.5% to 59.5%.
- September 14, 2026 — FDA clearance of Mint, 3D Intelligence submitted, Senseonics partnership announced.
- End of 2026 — planned U.S. launch of iLet 3D, subject to FDA clearance.
- First quarter of 2027 — planned start of the full U.S. commercial launch of Mint.
Why is Beta Bionics stock up today?
The FDA cleared Mint, Beta Bionics' first patch insulin pump, the company unveiled its 3D Intelligence dosing algorithm, and Senseonics agreed to integrate its Eversense 365 sensor with the iLet. At 12:22 ET the stock was at $17.29, up 4.34% on the session.
When will the Beta Bionics Mint patch pump launch?
Beta Bionics expects to begin the full U.S. commercial launch of Mint in the first quarter of 2027, selling it only through the pharmacy channel, with capacity for at least 1.5 million disposable units in 2027.
What is 3D Intelligence?
It is Beta Bionics' next insulin dosing algorithm, submitted to the FDA through a 510(k). It offers three selectable dosing experiences and is planned for iLet 3D by the end of 2026 and Mint 3D at Mint's full launch, subject to clearance.
How did Beta Bionics stock trade after the Mint clearance?
The stock printed $16.91 a minute after the 07:30 ET release. Later in the premarket 52,978 shares traded and the price fell to $14.24, 14.53% below the last print before the news; at 12:22 ET it was at $17.29.
Sources
-
Beta Bionics Announces FDA Clearance of Mint, the Company's Transformative Patch Pump, and Unveils 3D Intelligence as its Next-Generation Insulin Dosing Algorithm
— GlobeNewswire
FDA cleared Mint; specifications; 3D Intelligence submitted via 510(k); iLet 3D by end of 2026; capacity for at least 1.5 million disposable units in 2027; Mint modestly dilutive to 2027 gross margin.
-
Beta Bionics: FDA Clearance Of Mint Sets Stage For 2027 Patch Pump Launch
— RTTNews
FDA clearance of Mint sets up a 2027 patch pump launch.
-
Beta Bionics FDA Clears Mint Patch Pump in U.S.
— StockTitan
Mint commercialization in the first quarter of 2027 with pharmacy-channel exclusivity.
-
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense 365 with the iLet Bionic Pancreas
— GlobeNewswire
Senseonics will integrate Eversense 365 with the iLet; development completion and planned commercial launch in the fourth quarter of 2026.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Start Pro Watch live headlines -- free